Phase I Trial of Carboplatin, Paclitaxel, Etoposide, and Cyclophosphamide with Granulocyte Colony Stimulating Factor as First-Line Therapy for Patients with Advanced Epithelial Ovarian Cancer

By Tung N.   Berkowitz R.   Matulonis U.   Quartulli M.   Seiden M.   Kim Y.   Niloff J.   Cannistra S.A.  

Gynecologic Oncology, Vol. 77, Iss. 2, 2000-05 ,pp. : 271-277

Elsevier

Access to resources Recommend Favorite

Phase II trial of weekly docetaxel and gemcitabine as first-line therapy for patients with advanced non-small cell lung cancer

By Kalmadi Sujith   McNeill Giles   Davis Mellar   Peereboom David   Adelstein David   Mekhail Tarek  

Medical Oncology, Vol. 23, Iss. 4, 2006-12 ,pp. : 507-513

Humana Press, Inc

Access to resources Recommend Favorite

Phase II Trial of High-Dose Cisplatin Plus Ifosfamide as First-Line Followed by Carboplatin as Second-Line Treatment in Epithelial Ovarian Carcinoma

By Strauss G.   Lund B.   Hansen M.   Hansen H.H.  

Gynecologic Oncology, Vol. 66, Iss. 1, 1997-07 ,pp. : 66-70

Elsevier

Access to resources Recommend Favorite

A Phase I Study Of Docetaxel, Oxaliplatin, & Capecitabine (DOC) As First-Line Therapy of Patients With Locally Advanced or Metastatic Adenocarcinoma of Stomach and GE Junction

By Malik Imtiaz   Bernal Pedro   Byrd Janet  

Cancer Investigation, Vol. 28, Iss. 8, 2010-09 ,pp. : 833-838

Informa Healthcare

Access to resources Recommend Favorite

A multi-centre randomized, open-label phase II trial of continuous erlotinib plus gemcitabine or gemcitabine as first-line therapy in ECOG PS2 patients with advanced non-small cell lung cancer

By            

Oncology Reports, Vol. 28, Iss. 3, 2012-01 ,pp. : 763-767

Spandidos Publications

Access to resources Recommend Favorite